The drugmaker reported adjusted earnings per share of 92 cents, beating expectations of 67 cents, according to analysts polled by FactSet.

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Pfizer reaffirming its outlook for the full year but noting it has not factored in any potential impact from tariffs. Here to discuss what these results mean for the drug maker we've got Vamul Divan.

Seoul: Celltrion, a leading South Korean biopharmaceutical company, on Thursday said its business will remain largely ...

Pfizer CEO Albert Bourla on Tuesday said ... the guidance “does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict ...

Like his Big Pharma peers, Pfizer (PFE ... said the company is already expecting a $150 million impact in 2025 from the current slate of tariffs but did not detail which products are impacted.

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump's planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research ...

Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet ...

Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research operations and reported lower first-quarter revenue due to declining sales of its ...

Evaluate AbbVie Inc. vs. Pfizer Inc. amidst tariff disputes and drug pricing policies. Click for our comparison of ABBV and ...

Japanese automaker Nissan said it will shutter 7 plants and cut thousands of additional jobs in a second round of job cuts ...